Amarantus Bioscience Holdings, Inc. Form 4 November 20, 2014

November 2	20, 2014											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL		
Washington, D.C. 20549								OMB Number:	3235-0287			
Check th if no lon subject t Section Form 4 o Form 5 obligatio	ger o 16. or Filed pur	box								January 31, 2005 verage rs per 0.5		
may con See Instr 1(b).	tinue. Section 17(•	ding Con t Compan	· ·		1935 or Section				
(Print or Type	Responses)											
1. Name and A COMMISS	2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer						
		Amarantus Bioscience Holdings, Inc. [AMBS]					(Check all applicable)					
(1			3. Date of Earliest Transaction (Month/Day/Year)				-	X Director 10% Owner X Officer (give title Other (specify below) below)				
655 MONT SUITE 900	GOMERY STRE	ΈT,	11/20/2	014			·		CEO			
	(Street)			endment, Da nth/Day/Yea	ate Origina r)	l	1	5. Individual or Joi Applicable Line) _X_ Form filed by O	ne Reporting Pe	rson		
SAN FRAN	NCISCO, CA 941	11					- I	Form filed by Me Person	ore than One Re	porting		
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Secur	ities Acqui	ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deem Execution any (Month/Day/Year)			Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) ay/Year) (Instr. 8)					 A) 5. Amount of Securities Beneficially Owned Following Reported 	OwnershipInForm:BDirect (D)C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Common Stock	11/20/2014			Р	84,000	А	\$ 0.077	7,973,565	D			
Common Stock	11/20/2014			Р	36,000	А	\$ 0.075	8,009,565	D			
Common	11/20/2014			D	10.000		\$	0.010.565	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Р

10,000 A

11/20/2014

Stock

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form

8,019,565

0.0768

D

Edgar Filing: Amarantus Bioscience Holdings, Inc. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	7. Title Amour Underl Securit (Instr. 1	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address			Relationships						
			Officer	Other					
COMMISSIONG GERALD 655 MONTGOMERY STREET, SUITE 900 SAN FRANCISCO, CA 94111			CEO						
20/2014									
Date									
	7, SUITE 900 /20/2014	Director T, SUITE 900 X /20/2014	Director 10% Owner T, SUITE 900 X 220/2014	Director 10% Owner Officer C, SUITE 900 X CEO 20/2014					

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.